Editorial
doi: 10.1097/01.ccm.0000183002.26587.ff.
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial
- PMID: 16215410
- DOI: 10.1097/01.ccm.0000183002.26587.ff
Item in Clipboard
Editorial
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial
Crit Care Med.
2005 Oct.
No abstract available
Comment on
-
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.Crit Care Med. 2005 Oct;33(10):2266-77. doi: 10.1097/01.ccm.0000181729.46010.83. Crit Care Med. 2005. PMID: 16215381 Clinical Trial.
Similar articles
-
Drotrecogin alfa on trial.Lancet Infect Dis. 2009 Jan;9(1):2-3. doi: 10.1016/S1473-3099(08)70286-X. Lancet Infect Dis. 2009. PMID: 19095188 No abstract available.
-
Risks and benefits of activated protein C treatment for severe sepsis.N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574. N Engl J Med. 2002. PMID: 12324562 No abstract available.
-
Assessing the use of activated protein C in the treatment of severe sepsis.N Engl J Med. 2002 Sep 26;347(13):1030-4. doi: 10.1056/NEJMsb021512. N Engl J Med. 2002. PMID: 12324563 No abstract available.
-
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.Crit Care Med. 2003 Jan;31(1 Suppl):S94-6. doi: 10.1097/00003246-200301001-00013. Crit Care Med. 2003. PMID: 12544982 Review. No abstract available.
-
[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].Ugeskr Laeger. 2004 Mar 8;166(11):997-1002. Ugeskr Laeger. 2004. PMID: 15049234 Review. Danish. No abstract available.
Cited by
-
Evaluation of drotrecogin alpha use in a Belgian university hospital.Pharm World Sci. 2006 Oct;28(5):290-5. doi: 10.1007/s11096-006-9045-3. Epub 2006 Nov 17. Pharm World Sci. 2006. PMID: 17111246
-
Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.Drug Saf. 2007;30(11):995-1010. doi: 10.2165/00002018-200730110-00002. Drug Saf. 2007. PMID: 17973539 Review.
-
Medical guidelines and performance measures: the need to keep them free of industry influence.Mens Sana Monogr. 2008 Jan;6(1):22-8. doi: 10.4103/0973-1229.33005. Mens Sana Monogr. 2008. PMID: 22013347 Free PMC article. No abstract available.
-
Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?Crit Care. 2006;10(3):145. doi: 10.1186/cc4947. Epub 2006 Jun 2. Crit Care. 2006. PMID: 16762040 Free PMC article. Review.
-
When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated).Intensive Care Med. 2006 Apr;32(4):604; author reply 610-2. doi: 10.1007/s00134-006-0086-9. Epub 2006 Mar 1. Intensive Care Med. 2006. PMID: 16508757 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
